Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Express Scripts
Cantor Fitzgerald
Chubb
Cipla
Chinese Patent Office
Colorcon
Medtronic
Harvard Business School

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,879,828

« Back to Dashboard

Which drugs does patent 7,879,828 protect, and when does it expire?

Patent 7,879,828 protects TYGACIL and is included in one NDA.

This patent has twenty-five patent family members in twenty-three countries.
Summary for Patent: 7,879,828
Title:Tigecycline compositions and methods of preparation
Abstract:The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.
Inventor(s): Fawzi; Mahdi B. (Morristown, NJ), Zhu; Tianmin (Monroe, NY), Shah; Syed M. (East Hanover, NJ)
Assignee: Wyeth LLC (Madison, NJ)
Application Number:11/374,330
Patent Claim Types:
see list of patent claims
Composition; Formulation;

Drugs Protected by US Patent 7,879,828

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pf Prism Cv TYGACIL tigecycline POWDER;IV (INFUSION) 021821-001 Jun 15, 2005 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,879,828

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,694,078 Tigecycline compositions and methods of preparation ➤ Sign Up
8,975,242 Tigecycline compositions and methods of preparation ➤ Sign Up
9,254,328 Tigecycline compositions and methods of preparation ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Teva
Farmers Insurance
Federal Trade Commission
Covington
US Department of Justice
Baxter
Deloitte
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.